icovamenib
icovamenib: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Biomea Fusion, Inc. (BMEA) | Phase 2 |
FDA Decisions
FDA_MeetingCompany plans to engage with the FDA to discuss COVALENT-111 topline data and align on how to further advance icovamenib as a first-in-class menin inhibitor for T2D.(BMEA)
Frequently asked questions
Who is developing icovamenib?
icovamenib is being developed by Biomea Fusion, Inc..
What is icovamenib's latest FDA decision?
The most recent tracked FDA decision for icovamenib is FDA_Meeting for Company plans to engage with the FDA to discuss COVALENT-111 topline data and align on how to further advance icovamenib as a first-in-class menin inhibitor for T2D..
Get deeper analysis on icovamenib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis